NCT07175909 Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease
| NCT ID | NCT07175909 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hong Kong Polytechnic University |
| Condition | Dry Eye Disease (DED) |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2021-01-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the initial tear proteome profiles in Dry Eye Disease (DED) patients, the safety and effectiveness of using an EC certificate DED treatment device in DED management, together with the associated global tear proteome changes, will be investigated.
Eligibility Criteria
Inclusion Criteria: * OSDI score ≥ 13, and * Fail one of the three diagnostic tests: * Non-invasive tear break-up time (NITBUT) less than 10s; * Tears osmolarity higher than or equals to 308 mOsm/L or inter-ocular difference \> 8 mOsm/L; * When assessing with slit lamp, shows more than 9 spots of conjunctival stain with lissamine green, more than 5 spots of corneal stain with fluorescein or lid wiper epitheliopathy (LWE) with lissamine green ≥ 2 mm in length and/or ≥ 25% sagittal width. Exclusion Criteria: * Any active ocular infections, inflammations or anomalies in eyelid; * Pregnant or lactating; * Uncontrolled, newly diagnosed systemic diseases or with modified long-term medications within 6 months; * Carrying active implantable devices (e.g., pacemakers and hearing aids)
Contact & Investigator
Sung Hei Jimmy Tse
PRINCIPAL INVESTIGATOR
The Hong Kong Polytechnic University, Hong Kong,
Frequently Asked Questions
Who can join the NCT07175909 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Dry Eye Disease (DED). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07175909 currently recruiting?
Yes, NCT07175909 is actively recruiting participants. Contact the research team at jimmy.sh.tse@polyu.edu.hk for enrollment information.
Where is the NCT07175909 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07175909 clinical trial?
NCT07175909 is sponsored by The Hong Kong Polytechnic University. The principal investigator is Sung Hei Jimmy Tse at The Hong Kong Polytechnic University, Hong Kong,. The trial plans to enroll 75 participants.